Third-Party Social Media: Firms Should Not Be Selective In Corrections
This article was originally published in The Gray Sheet
Executive Summary
FDA’s draft guidance on correcting independent third-party misinformation about drugs and devices advises companies to address exaggerated efficacy claims as well as incorrect risk information.
You may also be interested in...
Will #Cures2015 Fix Twitter Promotion?
House 21st Century Cures discussion draft would adjust FDA promotion regulations for Twitter, requiring that information communicated through hyperlink be considered part of the original post.
Critics Call FDA Third-Party Social Media Guidance ‘Overbroad’
Some stakeholders are concerned the agency’s draft guidance is overreaching and could have a chilling effect. AdvaMed recommends FDA consider splitting the guidance into product-specific documents to reference regulations that may apply to industries differently.
FDA Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character-space limitations includes an equation for sending a tweet. Solving it for products with complex risk profiles could be a challenge.